Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

IMU raises £40m to read blood

2 min read
16:30UTC

IMU Biosciences closed an oversubscribed £40m Series A on 2 June, co-led by IQ Capital and Molten Ventures, with the British Business Bank co-investing on its second UK life-sciences cap table inside a fortnight.

← Back to Stryker agrees option to buy CMR SurgicalJump to analysis ↓
TechnologyDeveloping
Key takeaway

State capital is now a routine equity co-investor on British biotech cap tables beside specialist funds.

IMU Biosciences closed an oversubscribed £40m ($53m) Series A on Tuesday 2 June. IQ Capital and Molten Ventures co-led, with the British Business Bank (BBB) co-investing. Oversubscribed means investors sought more shares than the company offered. The platform extracts more than 100 million immune-system data points from a single blood sample, so one routine draw could replace a battery of separate immune tests.⁠1

The BBB had put £12m into Cytospire's £61m Series A in May and £50m into the Longwall deep-tech fund. Its £6.6bn expanded mandate lets it lead and co-invest directly in startups rather than backing them only through fund intermediaries.

That pattern reframes what UK state capital does at this stage. A development bank acting as a backstop appears when private money is absent; the BBB is appearing precisely where private money is already present, sitting beside IQ Capital and Molten on a priced biotech round. State capital is becoming a recurring line on British biotech cap tables rather than a substitute for the funds it sits beside.

Deep Analysis

In plain English

A standard blood test measures perhaps 20-50 different immune markers at once. IMU Biosciences has built a platform that measures over 100 million data points from a single blood sample, a four-to-five order of magnitude jump in resolution. Immune system data is medically useful because immune patterns appear early in many diseases, sometimes before other symptoms. At this density, IMU can identify correlations that simpler assays miss entirely: which patients will respond to a specific immunotherapy, or which immune signatures predict disease progression. The £40m raised funds the clinical validation studies needed to convert that data density into diagnostic products that hospitals and pharmaceutical companies will pay for.

What could happen next?
  • Precedent

    The BBB's third direct life-sciences co-investment in six weeks (Cytospire, Quantum Motion, IMU) establishes a pattern: UK state capital now participates routinely in private biotech rounds as a minority co-investor alongside specialist VCs.

  • Opportunity

    The 100-million-data-point density creates a pharmaceutical partnership opportunity: drug companies running immunology trials can pay per-assay fees for immune profiling at a resolution unavailable elsewhere.

Sources:UK Tech News·UK Tech News
Mentions:IQ Capital →British Business Bank →Cytospire Therapeutics →Longwall Ventures →IMU Biosciences →Molten Ventures →
First Reported In

Update #7 · OQC's £260m sets European quantum record

UK Tech News· 7 Jun 2026
Read original →
Causes and effects
Caused by
Cytospire's £61m oncology Series A oversubscribed
BBB's £12m co-investment in Cytospire's Series A in May established the direct BBB biotech co-investor pattern repeated in IMU Biosciences.
Occurred 5 May 2026
Read story →
State £50m backs the tier funds skip
BBB's £50m Longwall deep-tech fund cornerstone in May is part of the same expanded mandate that brought BBB onto IMU's cap table directly.
Occurred 27 May 2026
Read story →
Jobs plan targets the lab-skills gap
The plan addresses the same staffing gap IMU Biosciences' £40m AI-biotech round in June assumed was solved.
Occurred 9 Jul 2026
Read story →
This Event
IMU raises £40m to read blood
The state bank's repeat direct co-investment shows it acting as a routine equity partner in British biotech, not a lender of last resort.
Led to
Neubond seed is Japan VC's UK first
IMU Biosciences' £40m Series A is part of the UK-research-producing-companies pattern Neubond's Japanese-funded seed continues.
Occurred 15 Jun 2026
Read story →
Alchemab wins Bank's record £25m cheque
IMU Biosciences' £40m June round set the AI-biotech benchmark that Alchemab's £25m cheque extends.
Occurred 9 Jul 2026
Read story →
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.